Last mentioned: Mar 24, 2026
Retail Launch
CVS and Walgreens begin dispensing abortion pills in select states.
Dobbs Decision
U.S. Supreme Court overturns Roe v. Wade, allowing state-level bans.
FDA Rule Change
FDA officially allows retail pharmacies to dispense mifepristone with a prescription.
Data Stabilization
National reports confirm abortion rates remain steady despite ongoing state restrictions.
SCOTUS Ruling
Supreme Court preserves access to mifepristone by ruling plaintiffs lacked standing in FDA challenge.
Dobbs Decision
SCOTUS overturns Roe v. Wade, triggering state-level bans and increasing demand for pills.
Telehealth Shift
FDA permanently removes the requirement that mifepristone be dispensed in person.
Label Update
FDA expands usage to 70 days gestation and reduces required office visits.
FDA Approval
FDA approves Mifeprex (mifepristone) for medical termination of pregnancy.
Medication abortion has surged to account for the majority of pregnancy terminations in the U.S., driven by telehealth expansion and mail-order access. This shift has catalyzed a sophisticated legal and legislative counter-offensive aimed at the FDA's regulatory authority and the distribution of pharmaceutical products.
National data reveals that abortion rates in the United States have remained steady or increased despite a wave of state-level bans following the Dobbs decision. This trend is driven by a significant shift toward medication abortion and the rapid expansion of telehealth services protected by state shield laws.
This page surfaces every story mentioning GenBioPro across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where GenBioPro was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |